(3,5-dihydroxyphenyl)-spiro-isoxazolinyl parthenin | 1186630-12-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (3,5-dihydroxyphenyl)-spiro-isoxazolinyl parthenin
• 英文别名: (3aR,6S,6aS,9aS,9bR)-3'-(3,5-dihydroxyphenyl)-6a-hydroxy-6,9a-dimethylspiro[4,5,6,9b-tetrahydro-3aH-azuleno[8,7-b]furan-3,5'-4H-1,2-oxazole]-2,9-dione
• CAS: 1186630-12-5
• 化学式: C₂₂H₂₃NO₇
• 分子量: 413.427
• InChiKey: WYCGXVRWQVLSFP-MWEVVUQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3,5-dihydroxy-benzonitrile N-oxide 、 银胶菊宁 以 二氯甲烷 为溶剂， 反应 1.83h， 以69%的产率得到(3,5-dihydroxyphenyl)-spiro-isoxazolinyl parthenin
  参考文献：
  名称：

  [EN] SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS
  [FR] DÉRIVÉS SPIRO DE PARTHÉNINE SERVANT DE NOUVEAUX AGENTS ANTICANCÉREUX

  摘要：

  公开号：

  WO2009110007A8

文献信息

• Peptide-based multimeric targeted contrast agents
  申请人：Zhang Zhaoda

  公开号：US20050074411A1

  公开（公告）日：2005-04-07

  Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

  本文描述了肽和肽靶向多聚对比剂，以及制备和使用对比剂的方法。
• Spiro Derivatives of Parthenin as Novel Anticancer Agents
  申请人：Halmuthur Mahabalarao Sampath Kumar

  公开号：US20110201661A1

  公开（公告）日：2011-08-18

  The present invention relates to novel spiro derivatives of parthenin prepared by the dipolar cycloaddition of various dipoles viz, benzonitrile oxides, nitrones, azides, nitrile ylide diazoalkane, nitrile imide, ozone, azomethine imides, azomethine ylides etc. with exocyclic double bond of C ring (α-methylene-γ-butyrolactone). Representative compounds have been screened for their anticancer activity against different cancer cell lines. ICs0 value of these analogues varies between 4.3 μM to 93 μM. A mechanistic correlation of their anticancer activity has been described. The results of the cytotoxicity test of the compounds studies indicated that the α,β-unsaturated ketonic moiety in parthenin plays an important role in the maintenance of the high level of cytotoxicity.